Shuttle Pharmaceuticals
SHPH
3 hedge funds and large institutions have $158K invested in Shuttle Pharmaceuticals in 2023 Q3 according to their latest regulatory filings, with 1 funds opening new positions, increasing their positions, 1 reducing their positions, and 0 closing their positions.
50% more funds holding
Funds holding: 2 → 3 (+1)
0% less ownership
Funds ownership: 0% → 0% (-0%)
46% less capital invested
Capital invested by funds: $291K → $158K (-$132K)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Geode Capital Management
Boston,
Massachusetts
|
+$29.7K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Ayrton Capital
Westport,
Connecticut
|
-$24.7K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
AC
1
Ayrton Capital
Westport,
Connecticut
| $134K | -$24.7K | -15 | -12% |
|
|
2
Geode Capital Management
Boston,
Massachusetts
| $22.5K | +$29.7K | +18 | New |
|
|
FDCDDQ
3
Federation des caisses Desjardins du Quebec
Levis,
Quebec, Canada
| $1.16K | – | – | – |
|
|
TRCT
4
Tower Research Capital (TRC)
New York
| $63 | – | – | – |
|
5
Wells Fargo
San Francisco,
California
| $28 | – | – | – |
|
SHPH Hedge Fund Activity: Q3 2023 in Review
3 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Shuttle Pharmaceuticals (SHPH) for Q3 2023, worth a combined $158K — down 46% from $291K a quarter earlier.
Buyers outnumbered sellers: 1 fund opened new SHPH positions and 0 closed out — a net gain of 1 holder — while 0 added to existing stakes and 1 trimmed.
The largest buyer was Geode Capital Management, opening a new position worth an estimated $29.7K. The largest seller was Ayrton Capital, cutting an estimated $24.7K.
- 3 institutional investors held Shuttle Pharmaceuticals (SHPH) as of Q3 2023, up from 2 in Q2 2023.
- Funds reported $158K of Shuttle Pharmaceuticals stock for Q3 2023, down 46% quarter-over-quarter.
- 1 fund opened new Shuttle Pharmaceuticals positions in Q3 2023 and 0 closed out, a net change of +1 holder.
- The largest Shuttle Pharmaceuticals buyer in Q3 2023 was Geode Capital Management, an estimated $29.7K added.
- The largest Shuttle Pharmaceuticals seller in Q3 2023 was Ayrton Capital, an estimated $24.7K sold.
Based on aggregated 13F filings for Q3 2023.